-

Q-State Biosciences Announces Presentation at the World Orphan Drug Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced that Chief Scientific Officer, Graham Dempsey, PhD, will be giving an oral presentation at the upcoming 2021 World Orphan Drug Congress USA to be held August 25-27 in Oxen Hill, Maryland.

The presentation will detail the company’s fully integrated platform that enables ultra-large scale, high-quality data generation for unique, artificial intelligence/machine learning-driven insights into diseases of the central nervous system (CNS).

Presentation details are as follows:

Session Title:

 

Technology-enabled Drug Discovery Platform using Patient-derived Neuronal Models, High-throughput Optogenetics and Machine Learning

Session Date and Time:

 

August 25, 2021, 1:40 PM ET

About Q-State Biosciences

Q-State Biosciences is a discovery technology and therapeutics company that applies a proprietary multi-discipline platform to discover genetically targeted therapeutics for epilepsy, pain, and other disorders of the CNS. By integrating advanced human neuronal models, custom determinative measurement engineering and powerful AI/machine learning, we unlock unique insights into the biological complexity of the brain, its associated disease states and the creation of transformational medicines. For more information, please visit www.qstatebio.com.

Contacts

Business Development
Chani Maher
chani.maher@qstatebio.com
+1 617-945-5433

Media
Carolyn Noyes
cnoyes@macbiocom.com
+1 781-235-3060

Q-State Biosciences


Release Summary
Q-State Biosciences announces that CSO Graham Dempsey, PhD, will give an oral presentation at the 2021 World Orphan Drug Congress USA on August 25.
Release Versions

Contacts

Business Development
Chani Maher
chani.maher@qstatebio.com
+1 617-945-5433

Media
Carolyn Noyes
cnoyes@macbiocom.com
+1 781-235-3060

More News From Q-State Biosciences

Q-State Biosciences Announces New Peer Reviewed Publication Introducing Its Next Generation Swarm™ Optogenetic Measurement Technology System

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Q-State announces the publication of peer reviewed original research highlighting the company's proprietary Swarm™ technology system...

Q-State Publishes New Research on ASOs in Ultra-rare Neurodegenerative Disorder

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Q-State announces research on of splice modulating ASOs published in "Molecular Therapy Nucleic Acids."...

Q-State Biosciences Announces New Therapeutic Programs Targeting Neurodegeneration

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Q-State Biosciences announces a pipeline update introducing three advancing ASO discovery programs targeting rare neurodegenerative disorders....
Back to Newsroom